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Introduction
Type 2 diabetes represents a major challenge to health care 
because the numbers of affected individuals are on the rise 
not only in industrialised countries, and its micro- and 
macro-vascular complications can cause blindness, renal 
failure, amputations and increased cardiovascular morbid-
ity and mortality.1 Although type 2 diabetes is diagnosed 
by elevated blood glucose concentration, targeting hyper-
glycaemia as such has surprisingly yielded little to no ben-
efit in reducing diabetic complications or even mortality.2 
Therefore, the apparent incomplete understanding of the 
disease pathophysiology has led to the search for alterna-
tive clues tying different chronic conditions by unifying 
cellular mechanisms. Recently, an association between the 
C allele of the rs11212617 variant near the gene for ataxia 
telangiectasia mutated (ATM) has been demonstrated to 
affect the treatment response to metformin in human dia-
betes, possibly through modulating the activation of aden-
osine monophosphate–activated protein kinase (AMPK) 
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by metformin.3 ATM is a protein kinase that responds to 
DNA damage by phosphorylation of p53 and other targets 
but is also involved in insulin signalling.4 Previous data 
showed that heterozygous mutations in ATM (up to 1.4%–
2% of the general population) can lead to higher mortality 
and earlier death from coronary artery disease (CAD).5
The aim of our study was to test for an association 
between the rs11212617 near the ATM gene with CAD in 
men undergoing coronary angiography.
Materials and methods
A total of 253 men, ages from 58 to 86 years, were recruited 
from the University Hospital Heidelberg. All individuals 
had diagnosed or suspected CAD and underwent elective 
coronary angiography. The presence, severity and the 
extent of CAD were assessed as described previously.6 
Patient characteristics and biochemical parameters were 
determined in a standard clinical research setting as 
described.6 In all, 242 patients were enrolled and genotyped 
for the polymorphism at the locus near the ATM gene 
(rs11212617) using a TaqMan assay according to the manu-
facturer’s protocol (Life Science Technologies, Darmstadt, 
Germany). From 11 patients, DNA, serum or other essen-
tial information was missing. The study was approved by 
the Ethics Committee of the University of Heidelberg, and 
all participants gave written consent to the study. Statistical 
methods comprised chi-square test, comparisons of means 
by t-tests and analysis of variance (ANOVA) using loga-
rithmic transformation of non-parametric parameters, fol-
lowed by post hoc testing against the one group as baseline, 
as well as multivariate regression analyses, including anal-
ysis of covariance (ANCOVA) according to the general lin-
ear model using logarithmically transformed parameters. 
Data are expressed as mean ± 95% confidence interval 
(CI), on logarithmic scale where appropriate. Statistical 
analyses were performed using SPSS, release 19 (IBM 
SPSS Statistics, Chicago, IL, USA).
Results
The allele frequencies were 0.52 for the A allele and 0.48 for 
the C allele with 114 heterozygous subjects (CA). The allele 
frequencies were in accordance with the Hardy–Weinberg 
equilibrium (chi-square, p = 0.81). The characteristics of the 
study population according to the genotype are displayed in 
Table 1. Because the minor allele (C allele) occurred in 
nearly 50% of the subjects, we decided to employ a general 
model at first instance with genotype-based testing which 
treats the three genotypes as separate categories, leaving an 
additional degree of freedom as compared to weigh out a 
dominant or recessive model.
Previous results suggested an association of the C allele 
of the rs11212617 variant near the ATM locus with a ben-
eficial effect on HbA1c-lowering potential and a lower 
HbA1c when analysed in a quantitative trait.3 Although the 
effect on glucose-lowering potential could not be assessed 
in our cross-sectional cohort, we did not find a significant 
association between the rs11212617 variant and glucose 
concentration (data not shown). In contrast, we found a sig-
nificant higher frequency of CAD presence among carriers 
of the A allele (p = 0.003 by chi-square test of independ-
ence). This association was further substantiated by signifi-
cant higher logarithmically transformed quantitative CAD 
indices in presence of the A allele [severe score (SS): 0.5 
(0.4–0.6) vs 0.3 (0.2–0.5); extent score (ES): 2.63 (2.4–2.9) 
vs 1.94 (1.4–2.4), both p < 0.05, respectively] and by an 
association between the mere A allele presence and the 
logarithmically transformed markers of CAD (Table 1).
Being aware of the fact that the associations were con-
sistent but modest, we tested for independent effects 
employing a multivariate regression analysis using ES as 
dependent variable and several demographic and meta-
bolic parameters known to be associated with atheroscle-
rosis as confounding factors [age, body mass index (BMI), 
lipid and fasting glucose levels, smoking, previous myo-
cardial infarction, hypertension and statin use]. The results 
revealed an independent association between the A allele 
and ES of CAD (β = 0.17, p < 0.01; Table 2) with an effect 
size at least equally powerful as compared to the influence 
of low-density lipoprotein (LDL) cholesterol or hyperten-
sion. Equal results were obtained for SS in multivariate 
analysis (data not shown). The distribution of CAD ES 
and SS (Table 1) suggested testing for a dominant model 
for AA/CA versus CC. This comparison yielded a nearly 
significant difference in SS of CAD [0.34 (0.2–0.4) vs 0.5 
(0.4–0.5), p = 0.06] and a significant difference of ES [1.9 
(1.48–2.32) versus 2.6 (2.31–2.79), p = 0.01] in an 
ANCOVA of logarithmically transformed scores accord-
ing to the general linear model using the same confound-
ing variables as indicated above.
Conclusion
The pathogenesis and pathophysiology of type 2 diabetes 
and its complications are despite the pandemic dimension 
of diabetes incompletely understood,1 hence the contribu-
tion of isolated hyperglycaemia and/or its correction to 
CAD is not clear.2 Targeting a cluster of different risk fac-
tors at a time, which account for the so-called metabolic 
syndrome, seems to be more effective in reducing vascular 
disease. The question becomes, however, whether these 
metabolic syndrome components are disparate or share a 
unifying, yet unknown underlying mechanism,7 following 
Barabasi’s basic concept of complex cellular networks 
underlying genotype-to-genotype relationships.8
The report on the association between the variant 
rs11212617 near the ATM gene and metformin treatment 
response suggests the participation of ATM, a DNA repair 
enzyme, in metabolic diseases.3 While this finding is 
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Table 1. Clinical characteristics of patients according to rs11212617 genotype.
Factor CC (n = 58) CA (n = 114) AA (n = 70)
Age (years) 60.0 (57.5–62.6) 62.8 (61.0–65.0) 60.7 (58.1–63.2)
BMI (kg/m2) 27.1 (26.3–27.9) 27.8 (27.2–28.5) 27.4 (26.5–28.2)
Cholesterol (mg/dL)
Total 212.7 (200.1–225.3) 203.3 (195.1–211.6) 203.1 (191.5–214.7)
HDL 41.2 (38.4–43.9) 40.0 (37.6–42.3) 38.8 (36.1–41.5)
LDL 146.2 (135.8–156.4) 138.0 (131.6–144.4) 140.7 (129.8–151.6)
VLDLa 1.29 (1.2–1.4) 1.3 (1.2–1.4) 1.3 (1.2–1.4)
Triacylglycerola 2.11 (2.0–2.2) 2.1 (2.1–2.15) 2.0 (2.0–2.14)
Atherosclerosis risk index 5.3 (4.9–5.7) 5.6 (5.0–6.1) 5.7 (5.2–6.2)
Fasting plasma glucose (mg/dL) 111.7 (102.6–120.6) 113.5 (106.2–122.4) 115.3 (104.4–124.2)
Pack yearsa 3.2 (2.9–3.4) 3.1 (2.9–3.3) 3.1 (2.8–3.4)
Hs-CRPa 0.25 (0.12–0.38) 0.29 (0.18–0.38) 0.20 (0.07–0.31)
SSa 0.34 (0.2–0.46) 0.46 (0.36–0.54) 0.52 (0.41–0.64)*
ESa 1.9 (1.44–2.4) 2.5 (2.2–2.9)* 2.8 (2.4–3.2)**
Previous MI 38% 33% 35%
Statin use 38% 50% 48%
Hypertension 45% 54% 49%
BMI: body mass index; HDL: high-density lipoprotein; LDL: low-density lipoprotein; VLDL: very low-density lipoprotein; Hs-CRP: high sensitivity C-
reactive protein; SS: severe score; ES: extent score; MI: myocardial infarction; CI: confidence interval; ANOVA: analysis of variance.
Values are mean ± 95% CI. Bold variables were entered into multivariate analysis.
aLog-transformed parameter ± 95% CI from univariate analyses.
*p < 0.05, **p < 0.01, ANOVA of log-transformed values.
Table 2. Multiple regression analysis result of variables with significant effect on CAD extent.
Independent variable T 95% CI p value
rs11212617 2.7 1.7 to 10.7 0.008
BMI 1.22 −0.378 to 1.6 0.2
Age 2.7 0.13 to 0.83 0.008
LDL cholesterol 1.5 −0.04 to 0.30 0.1
HDL cholesterol −0.86 −0.78 to 0.32 0.4
Atherogenic index −0.7 −6.9 to 3.3 0.5
Hs-CRP −1.12 −0.89 to 0.23 0.2
Fasting glucose 0.26 −1.5 to 2.0 0.8
Smoking 2.1 0.015 to 0.34 0.03
Previous MI 4.9 11.3 to 26.2 <0.001
Hypertension 2.0 0.24 to 14.2 0.045
Statin 2.9 3.2 to 17.0 0.004
CAD: coronary artery disease; CI: confidence interval; BMI: body mass index; LDL: low-density lipoprotein; HDL: high-density lipoprotein; Hs-CRP: 
high sensitivity C-reactive protein; MI: myocardial infarction.
The dependent variable is ES (a.u.); r2 = 0.371. T represents the estimated coefficient, divided by its own standard error. T values below −2 or above 
2 are considered as useful predictors in the model.
seemingly unexpected, links between DNA-damage 
response and metabolic or vascular diseases in mice have 
been published before.9,10
These data prompted us to study the potential influence 
of this variant on CAD in humans. Our data show a signifi-
cant correlation between the A allele of rs11212617 and SS 
and ES in men. This association was independent of other 
potential confounding factors in a multivariate analysis 
(Table 2). Our results may actually corroborate a proposed 
beneficial effect of the C allele of rs11212617 on metform-
in’s effect on lowering HbA1c,3 by a possibly accompanied 
beneficial effect on vascular disease, but this hypothesis is 
very speculative and lacks a mechanistic explanation. 
However, besides an effect of the ATM kinase on AMPK 
activity,3 other modes of action also qualify for an ATM-
mediated influence on metabolic vascular disease, including 
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the involvement of reactive oxygen species (oxidative stress) 
and other stress-related signalling.11 In fact, it seems that 
various effects differentially regulate/modulate the effects 
that link ATM to metabolic vascular diseases.12
Our study suffers from limitations such as the moderate 
subject number of males only and the lack of haplotype 
genotypic data. However, a recent study corroborates our 
findings. The authors showed a significant correlation 
between functional polymorphism (rs189037) in the ATM 
promoter region, with lower ATM expression associated 
with the degree of CAD as well as with diabetes mellitus 
prevalence in the Chinese cohort.13
In conclusion, the rs11212617 variant near the ATM 
gene is associated with CAD in men, which suggests that 
ATM activity may be associated with cardiovascular dis-
ease by complex underlying mechanistic network. The 
observed association and the missing underlying explana-
tion warrant further basic research efforts and epidemio-
logical evidence.
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